local coverage determination | GenomeWeb

local coverage determination

The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.

Palmetto GBA revised a final LCD for comprehensive genomic profiling in lung cancer, and issued similar draft determinations in other cancers.

In a final policy on comprehensive genomic profiling, Palmetto said that approved registries will have to commit to sharing data, among other requirements. 

A recent draft local coverage determination from Medicare contractor Noridian is one step along a growth path, according to Veracyte's CEO.

The firm expects the final LCD will go into effect around the beginning of next year, and that three remaining Medicare contractors will soon post draft LCDs for its test. 

While undergoing parallel review for its FoundationOne test by the FDA and CMS, the firm will continue to work with its local MACs on reimbursement.

Noridian said it has identified new data that will "significantly impact" its proposed policy on biomarker tests for guiding adjuvant chemotherapy decisions.

Noridian proposes to cover several biomarker tests for guiding chemotherapy decisions for breast cancer patients with node-negative disease but not when it's node positive.

Medicare contractors Palmetto GBA, Noridian Healthcare Solutions, and CGS Administrators have all proposed reimbursement coverage for the ProMark test.

Immucor's PreciseType evaluates blood compatibility between donors and patients to help prevent mismatches that can cause potentially life-threatening reactions.

Pages

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.